Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of Certain Officers. To the extent required by Item 5.02 of Form 8-K, the information contained in Item 8.01 of this Cur |
| 29.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ecutive Compensation The information set forth in Item 5.02 of this Current Report on Form 8-K is incorporated herein by |
Stammdaten
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Unternehmen & Branche
| Name | ImageneBio, Inc. |
|---|---|
| Ticker | IMA |
| CIK | 0001835579 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 66,3 Mio. USD |
| Beta | 0,55 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 800,000 | -45,349,000 | -9.64 | 152,976,000 | 133,139,000 |
| 2025-09-30 | 10-Q | 800,000 | -24,779,000 | -2.91 | 160,878,000 | 139,832,000 |
| 2025-06-30 | 10-Q | -7,585,000 | -0.06 | 126,166,000 | -180,351,000 | |
| 2025-03-31 | 10-Q | -6,077,000 | -0.18 | 130,838,000 | -169,600,000 | |
| 2024-12-31 | 10-K | 3,500,000 | -36,568,000 | -22.10 | 15,922,000 | -160,565,000 |
| 2024-09-30 | 10-Q | 3,500,000 | -3,183,000 | -2.58 | 148,988,000 | -152,754,000 |
| 2024-06-30 | 10-Q | -6,259,000 | -0.28 | 157,485,000 | -146,575,000 | |
| 2024-03-31 | 10-Q | -22,314,000 | -0.33 | 172,782,000 | -137,346,000 | |
| 2023-12-31 | 10-K | 9,160,000 | -68,166,000 | -1.63 | 192,092,000 | -126,108,000 |
| 2023-09-30 | 10-Q | 1,185,000 | -17,343,000 | -0.40 | 215,335,000 | 155,344,000 |
| 2023-06-30 | 10-Q | 2,004,000 | -17,115,000 | -0.44 | 171,764,000 | 156,700,000 |
| 2023-03-31 | 10-Q | 5,313,000 | -14,219,000 | -0.39 | 152,401,000 | 135,022,000 |
| 2022-12-31 | 10-K | 15,618,000 | -68,765,000 | -1.90 | 172,259,000 | 146,969,000 |
| 2022-09-30 | 10-Q | 6,402,000 | -17,338,000 | -0.48 | 190,468,000 | 158,788,000 |
| 2022-06-30 | 10-Q | 382,000 | -20,491,000 | -0.57 | 211,184,000 | 174,368,000 |
| 2022-03-31 | 10-Q | 3,384,000 | -16,839,000 | -0.47 | 227,747,000 | 192,955,000 |
| 2021-12-31 | 10-K | 30,985,000 | -34,115,000 | -1.22 | 247,879,000 | 207,877,000 |
| 2021-09-30 | 10-Q | 3,746,000 | -14,515,000 | -0.40 | 261,705,000 | 203,263,000 |
| 2021-06-30 | 10-Q | 3,549,000 | -12,681,000 | -0.35 | 278,827,000 | 216,260,000 |
| 2021-03-31 | 10-Q | 3,474,000 | -9,716,000 | 293,662,000 | 227,644,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-24 | SLATTERY JOSEPH P | Director | Open Market Purchase | 16,000 | 5.99 | 95,840.00 | +2,7% | |
| 2025-07-25 | Bonita David P | Director | Open Market Purchase | 83,611 | 29.90 | 2,499,968.90 | +70,8% | |
| 2025-07-25 | Stampacchia Otello | Director | Open Market Purchase | 267,556 | 29.90 | 7,999,924.40 | +226,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.